Occipital nerve stimulation for intractable chronic cluster headache or migraine: A critical analysis of direct treatment costs and complications. (December 2013)

• Record Type: Journal Article
• Authors: Mueller, Oliver; Diener, Hans-Christoph; Dammann, Philipp; Rabe, Kasja; Hagel, Vincent; Sure, Ulrich; Gaul, Charly
• Is Part Of: Cephalalgia. Volume 33:Number 16(2013)
• Page Start: 1283
• Page End: 1291
• Publication Date: 2013-12
• Subjects: Chronic cluster headache -- chronic migraine -- occipital nerve stimulation (ONS) -- treatment costs -- complications -- outcome; Headache -- Periodicals; 616.8491
• DOI: 10.1177/0333102413493193
• Languages: English
• ISSNs: 0333-1024

Abstract

Background: Occipital nerve stimulation (ONS) has been shown to be effective for selected patients with intractable headache disorders. We performed a prospective critical evaluation of complications and direct treatment costs. Methods: Twenty-seven patients with chronic cluster headache (CCH, n = 24) or chronic migraine (CM, n = 3) underwent a trial phase with bilateral ONS and subsequent implantation of a permanent generator (IPG), if responsive to treatment according to predefined criteria. Procedural and long-term complications as well as direct treatment costs of neuromodulation therapy of ONS were recorded over a mean follow-up period of 20 months (range 5–47 months). Results: Twenty-five of 27 patients (93%) responded to treatment. Twenty-one complications in 14 patients were identified, necessitating reoperation in 13 cases. Overall treatment costs were €761, 043, including hardware-related costs of €506, 019, costs for primary hospital care of €210, 496, and complications related to hospitalization costs of €44, 528. This results in a per case-based cost of €9445 for hospitalization and €18, 741 for hardware costs, totaling €28, 186. Conclusion: ONS for treatment of refractory CCH and CM is a cost-intensive treatment option with a significant complication rate. Nevertheless, patients with refractory primary headache disorders may experience substantial relief of pain attacks, and headache days, respectively.